These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30455317)

  • 1. Biological sex affects vaccine efficacy and protection against influenza in mice.
    Fink AL; Engle K; Ursin RL; Tang WY; Klein SL
    Proc Natl Acad Sci U S A; 2018 Dec; 115(49):12477-12482. PubMed ID: 30455317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Greater Breadth of Vaccine-Induced Immunity in Females than Males Is Mediated by Increased Antibody Diversity in Germinal Center B Cells.
    Ursin RL; Dhakal S; Liu H; Jayaraman S; Park HS; Powell HR; Sherer ML; Littlefield KE; Fink AL; Ma Z; Mueller AL; Chen AP; Seddu K; Woldetsadik YA; Gearhart PJ; Larman HB; Maul RW; Pekosz A; Klein SL
    mBio; 2022 Aug; 13(4):e0183922. PubMed ID: 35856618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice.
    Jeisy-Scott V; Kim JH; Davis WG; Cao W; Katz JM; Sambhara S
    J Virol; 2012 Oct; 86(20):10988-98. PubMed ID: 22837197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
    Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
    Front Immunol; 2018; 9():2312. PubMed ID: 30356772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
    Kamlangdee A; Kingstad-Bakke B; Osorio JE
    J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.
    Sarawar S; Hatta Y; Watanabe S; Dias P; Neumann G; Kawaoka Y; Bilsel P
    Vaccine; 2016 Sep; 34(42):5090-5098. PubMed ID: 27595896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    Quan FS; Huang C; Compans RW; Kang SM
    J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.
    Brazzoli M; Magini D; Bonci A; Buccato S; Giovani C; Kratzer R; Zurli V; Mangiavacchi S; Casini D; Brito LM; De Gregorio E; Mason PW; Ulmer JB; Geall AJ; Bertholet S
    J Virol; 2016 Jan; 90(1):332-44. PubMed ID: 26468547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8(+)-mediated cross protection against influenza.
    Baranowska M; Hauge AG; Hoornaert C; Bogen B; Grødeland G
    Vaccine; 2015 Dec; 33(49):6988-96. PubMed ID: 26387432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the European Avian-like H1N1 swine influenza virus in mice and pigs.
    Ruan BY; Wen F; Gong XQ; Liu XM; Wang Q; Yu LX; Wang SY; Zhang P; Yang HM; Shan TL; Zheng H; Zhou YJ; Tong W; Gao F; Tong GZ; Yu H
    Vet Microbiol; 2018 Aug; 222():75-84. PubMed ID: 30080677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linear DNA vaccine prepared by large-scale PCR provides protective immunity against H1N1 influenza virus infection in mice.
    Wang F; Chen Q; Li S; Zhang C; Li S; Liu M; Mei K; Li C; Ma L; Yu X
    Vet Microbiol; 2017 Jun; 205():124-130. PubMed ID: 28622854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against homo and hetero-subtypic influenza A virus by optimized M2e DNA vaccine.
    Yao Y; Wang H; Chen J; Shao Z; He B; Chen J; Lan J; Chen Q; Chen Z
    Emerg Microbes Infect; 2019; 8(1):45-54. PubMed ID: 30866759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.